Axsome Therapeutics (AXSM) Gross Profit (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Gross Profit data on file, last reported at $176.5 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 58.03% year-over-year to $176.5 million; the trailing twelve-month figure through Mar 2026 stood at $655.8 million (up 136.68% YoY), and the FY2025 full-year result was $591.0 million, up 67.72% from the prior year.
• Gross Profit slipped to $176.5 million in Q1 2026, from $183.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $183.7 million in Q4 2025 to a low of -$10.0 million in Q4 2024.
• A 5-year average of $80.7 million and a median of $73.9 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit tumbled 115.61% in 2024 and surged 1934.13% in 2025, its largest moves.
• Tracing AXSM's Gross Profit over 5 years: stood at $22.1 million in 2022, then jumped by 190.54% to $64.2 million in 2023, then plunged by 115.61% to -$10.0 million in 2024, then surged by 1934.13% to $183.7 million in 2025, then retreated by 3.92% to $176.5 million in 2026.
• Business Quant data shows AXSM's Gross Profit at $176.5 million in Q1 2026, $183.7 million in Q4 2025, and $159.1 million in Q3 2025.